The association between body mass index and the risk of different urinary cancers
Protocol for an overview of systematic reviews
Wenli Zhao, MD, Jiyuan Shi, MM, Yamin Chen, MM, Ziwei Song, MM, Liangliang Si, MM, Xin Jiang, MM, Yu Gu, MM

Abstract
Background: The relationship between cancer with body mass index has been extensively reported. However, association between urinary cancers with these risk factors remains unclear, with existing reports showing conflicting findings. The current review, therefore, sought to clarify the latter association by assessing the methodological and reporting quality of existing systematic reviews on the subject.

Methods: We will screen PubMed, EMBASE, and Cochrane Library databases for relevant literature and subjected the resulting articles to meta-analysis. We will adopt the AMSTAR and PRISMA checklists for assessing methodological, and reporting quality, respectively. The association between BMI and different urinary cancers will be estimated by computing the pooled relative risk (RR) and its 95% confidence interval (CI), which will be calculated from the adjusted RR, odds ratio, or hazard ratio, and 95% CI offered in the studies. Heterogeneity between studies will be assessed with the I statistic as a measure of the proportion of total variation in estimates that is due to heterogeneity, where I values of 25%, 50%, and 75% correspond to cut-off points for low, moderate, and high degrees of heterogeneity. The random effects model will be used as the pooling method when significant heterogeneity existed and the fixed effect model will be used when no heterogeneity was observed. Possible publication bias will be tested by Begg and Egger test.

Conclusion: Our evidence synthesis will provide a new commentary on the current systematic review evidence for the association between BMI and the risk of different urinary cancers.

PROSPERO registration number: CRD42019119459.

Abbreviations: AMSTAR = assessment of assessment of multiple systematic reviews, BMI = body mass index, CI = confidence interval, HR = Hazard ratio, OR = Odds ratio, PRISMA = preferred reporting items for systematic reviews and meta-analyses, RR = the relative risk, SR = systematic review.

Keywords: cancer, meta-analysis, obesity, overweight

1. Introduction
Cancer is the second most deadly disease affecting human health worldwide.[1] According to the Global Cancer Statistics of 2018, published by the World Health Organization/International Agency for Research on Cancer,[2] prostate cancer represents the second most common type of cancer and the fifth leading...
cause of cancer-related deaths in men. For example, this type caused an estimated 1.3 million new cases and 359,000 deaths in 2018 alone, whereas bladder cancer accounted for 549,000 new cases and 20 million deaths worldwide. The incidence of bladder cancer (9.6/100,000) as well as mortality rate (3.2/100,000) are about four times (2.4/100,000 and 0.87/100,000) that of females. On the other hand, kidney cancer caused >400,000 new cases, and 170,000 deaths in the same year. These figures underscore the incidence and impact caused by the three types of cancers across the world, although the underlying mechanism of their development remains unclear owing to limited evidence. Previous studies have suggested that cumulative effects of cigarette smoking, alcohol consumption, obesity, and genetic susceptibility may be risk factors for urinary cancer. Accurate smoking, alcohol consumption, obesity, and genetic susceptibility may be risk factors for urinary cancer. Accurate understanding of these risk factors is critical for the development of effective approaches for cancer prevention and treatment.

Overweight and obesity are defined as excess body weight that causes many chronic diseases and increases the risk of death. The number of overweight and obese adults had risen to 2.1 billion in 2013, with direct costs resulting from obesity estimated to account for 0.7 to 2.8% of a country’s total healthcare expenditures. In USA, Wang et al predicted a $48 to $66 billion increase per year in combined medical costs from common obesity-related diseases by 2030. Policymakers in the public health sector rely on high-quality evidence, generated by meta-analyses and SR, to formulate policies for the prevention and management of cancer. However, despite numerous SRs describing the relationship between cancer with overweight and obesity, over the past several decades, conflicting findings regarding the association of these risks factors with urinary cancers pose a challenge to accurate understanding of their epidemiology as well as the development of management approaches.

In the current study, we sought to generate more comprehensive and robust evidence of the relationship between the urinary cancers with obesity and overweight using a meta-analysis of published literature.

2. Material and methods

2.1. Protocol registration

This overview was registered by the International prospective register of systematic reviews (PROSPERO), number CRD42019119439.

2.2. Searching

Two reviewers will independently search the PubMed, Cochrane Library, and Embase databases. The search was limited to articles written in English and used the following search terms: BMI, obesity, cancer, carcinoma, neoplasm, meta-analysis, and SRs. A detailed description of the PubMed search strategy is presented in the Data S1.

2.3. Screening and selection procedure

Studies will be included if:

1. SRs or meta-analysis associated obesity, and overweight with urinary cancer;
2. SRs or meta-analysis associated increase in BMI with urinary cancer;
3. Articles were published in English;
4. Latest article was included when SRs or meta-analysis had been updated.

Studies were excluded if:

1. They were only abstracts and/or letters;
2. SRs and meta-analysis examined the association between BMI increase and prognosis, survival or recurrence of urinary cancers;
3. Protocols of SRs and meta-analysis or methodological articles;
4. SRs without meta-analysis.

2.4. Study selection and data retrieval

The retrieved articles were first imported into EndNote X7 software, then titles and abstracts independently selected by two reviewers. The reviewers thereafter retrieved full texts of potentially eligible studies and independently subjected them to the aforementioned criteria. Any disagreement was discussed with a third reviewer. The 2 reviewers independently extracted the following characteristic from each study: first author's name, year of publication, funding, number of reference test, name of database, country of first author, the epidemiological study design (case-control or cohort), number of cases, features of the urinary cancers, summary effects between BMI and cancer risk (at 95% CI), and the number of included studies.

2.5. Methodological and reporting quality assessment

To assess methodological quality, we will use the AMSTAR checklist, which comprises 11 items. Total AMSTAR scores will be denoted as 1 point for “Yes” (item/question fully solved), no point for “No” (item/question not solved), or “partial answer” (item not fully solved). Obvious, moderate and minimal flaws will be defined using <4, 5–8, and <9 points, respectively as previously described. To assess the reporting quality of included SRs and meta-analyses, we will use the PRISMA checklist, which comprises 27 items. To show the degree of compliance, total PRISMA scores will be calculated by summing 1 point for “Yes” (total confirmed), 0.5 points for “Partial” (partial confirmed) and “Cannot answer” (limited information), 0 point for “No” (noncompliance). The SR and meta-analysis will be regarded low quality if PRISMA scores are below 15 points, moderate if they recorded 15.0 to 21.0 points, and high if >21.0 points are recorded. Quality assessment of the included SRs and meta-analyses will be independently performed by two authors (JYS and LLS), and any disagreements between them will be discussed with a third author (JHT).

2.6. Statistical analysis

We will calculate pooled RRs (at 95% CI) from included SRs and meta-analysis (HRs and ORs equivalent to RR) records using the fixed effects model or random-effects model. A condition is considered normal if a BMI of 18.5–24.9 kg/m² was recorded, overweight for 25 to 29.9 kg/m², and obesity for BMI >30 kg/m². We will also analyze each 1 kg/m² and 5 kg/m² increase in BMI according to previous protocols. In addition, we will assess the heterogeneity between studies using the I² statistic. Specifically, we will adopt the fixed-effect model when I² value was less than 50%, and the random-effect model for an I² value
greater than 50%.[21] Possible publication bias will be tested by Begg and Egger test.[21] Furthermore, we will analyze indirect comparisons of the outcomes across the meta-analyses. Statistical analyses will be performed using STATA software (version 12.0, College Station, TX), with values that have $P \leq 0.05$ considered statistically significant. Bubble diagram will be constructed to visualize the methodological quality and the quality of included literature.

3. Discussion

Methodological and reporting quality of meta-analysis and SRs are crucial to public health and clinical decision making. Despite numerous studies analyzing cancer risk factors, no consensus has been reached regarding the relationship between different urinary cancer with obesity and overweight. In the current study, we sought to generate more comprehensive and robust evidence of the relationship between the urinary cancers with obesity and overweight using a meta-analysis of published literature.

Acknowledgments

We express our thanks to Jinhui Tian for the assistance with the design of the protocol.

Author contributions

JS and LLS conceived the idea for this study; JS, XJ, YG, and WLZ drafted the protocol. All authors approved the article in its final form.

Writing – original draft: Jiyuan Shi.

References

[1] Al-Othman S, Haoudi A, Alhomoud S, et al. Tackling cancer control in the Gulf cooperation council countries. Lancet Oncol 2015;16:e246–57.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[3] Wong Ho C, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245–57.
[4] Yaxley JP. Urinary tract cancers: an overview for general practice. J Family Med Prim Care 2016;5:533–8.
[5] Marie N, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–81.
[6] Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011;12:131–41.
[7] Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378:815–25.
[8] Hinotsu S, Namiki M, Ozono S, et al. NCCN Asia Consensus Statement prostate cancer. Jpn J Clin Oncol 2018;48:964–5.
[9] Sasazuki S, Inoue M, Shimazu T. Evidence-based cancer prevention recommendations for Japanese. Jpn J Clin Oncol 2018;48:576–86.
[10] Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3:e3081.
[11] Xing D, Wang B, Zhang W, et al. Intra-articular platelet-rich plasma injections for knee osteoarthritis: an overview of systematic reviews and risk of bias considerations. Int J Rheum Dis 2017;20:1612–30.
[12] Xu C, Liu Y, Zhang C. An overview on the methodological and reporting quality of dose–response meta-analysis on cancer prevention. J Cancer Res Clin 2019;145:1201–11.
[13] Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012;19:2212–23.
[14] Gao Y, Li J, Ma X, et al. The value of four imaging modalities in diagnosing lymph node involvement in rectal cancer: an overview and adjusted indirect comparison. Clin Exp Med 2019;19:225–34.
[15] Ge L, Tian JH, Li XX, et al. Epidemiology Characteristics, Methodological Assessment and Reporting of Statistical Analysis of Network Meta-Analyses in the Field of Cancer. Sci Rep 2016;6:37208.
[16] Li J, Ge L, Ma JC, et al. Quality of reporting of systematic reviews published in "evidence-based" Chinese journals. Syst Rev 2014;3:58.
[17] Monasta L, Batty GD, Cattaneo A, et al. Early-life determinants of overweight and obesity; a review of systematic reviews. Obes Rev 2010;11:695–708.
[18] Greenland S, Longnecker MP. Methods for trend estimation from summarized dose–response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301–9.
[19] Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose–response data. Stata J 2006;6:40–57.
[20] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[21] Seagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ 1998;316:470–1.